Reply: Clinical efficacy of lenvatinib for the treatment of radioiodine-refractory thyroid carcinoma: A systematic review and meta-analysis of clinical trials

Clin Endocrinol (Oxf). 2023 Feb;98(2):275-276. doi: 10.1111/cen.14718. Epub 2022 Mar 15.

Authors

Jingyang Su¹, Yue Fu¹, Menglei Wang¹, Shengyou Lin²

Affiliations

¹ Hangzhou Hospital of Traditional Chinese Medicine affiliated to Zhejiang Chinese Medicine University, Hangzhou, China.
² Department of Oncolgy, Hangzhou Hospital of Traditional Chinese Medicine affiliated to Zhejiang Chinese Medical University, Hangzhou, China.

PMID: 35261050
DOI: 10.1111/cen.14718

No abstract available

Keywords: lenvatinib; meta-analysis; radioiodine-refractory thyroid carcinoma; systematic review.

Publication types

Meta-Analysis
Systematic Review
Letter
Comment

MeSH terms

Antineoplastic Agents* / therapeutic use
Humans
Iodine Radioisotopes / therapeutic use
Phenylurea Compounds / therapeutic use
Quinolines* / therapeutic use
Thyroid Neoplasms* / drug therapy
Thyroid Neoplasms* / radiotherapy
Treatment Outcome

Substances

lenvatinib
Iodine Radioisotopes
Phenylurea Compounds
Quinolines
Antineoplastic Agents